Related Experiment Video
Updated: Aug 4, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
WT1 expression level and clinical factors in multiple myeloma
Y Hatta1, J Takeuchi, T Saitoh
1Dept. of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan. yhatta@med.nihon-u.ac.jp
Journal of Experimental & Clinical Cancer Research : CR
|February 14, 2006
Summary
Wilms Tumor gene (WT1) expression is lower in multiple myeloma than leukemia but correlates with disease severity. WT1 may serve as an additional marker for assessing multiple myeloma risk.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Wilms Tumor gene (WT1) is a known tumor suppressor, implicated in Wilms tumor and overexpressed in leukemia.
- WT1's role in multiple myeloma (MM) pathogenesis and clinical significance remains unclear.
- Minimal residual disease detection in acute leukemia utilizes WT1 expression.
Purpose of the Study:
- To investigate the clinical relevance of WT1 gene expression in newly diagnosed multiple myeloma patients.
- To determine the association between WT1 expression levels and various clinical parameters in MM.
Main Methods:
- Examined WT1 expression in bone marrow samples from 17 newly diagnosed multiple myeloma patients.
- Utilized real-time quantitative polymerase chain reaction (RQ-PCR) to assess WT1.
- Calculated standardized WT1 expression per 100 plasma cells ('corrected WT1').
Main Results:
- WT1 expression levels in myeloma were lower compared to leukemia.
- WT1 transcripts significantly increased with worsening clinical factors, including stage, M protein levels, and markers of organ function and inflammation (Hb, BUN, creatinine, ALP, calcium, beta2-microglobulin, TK, CRP).
Conclusions:
- WT1 expression levels correlate with disease progression and severity in multiple myeloma.
- WT1 may serve as a valuable supplementary biomarker for risk stratification in multiple myeloma patients.
